Subclinical impairment of ovarian reserve in systemic lupus erythematosus patients with normal menstruation not using alkylating therapy

Journal of Women's Health

Volumn 22, Issue 12, 2013, Pages 1023-1027

  Ma, Wenhong ^a,b   Zhan, Zhongping ^a   Liang, Xiaoyan ^a   Chen, Jianhui ^a   Huang, Xingfang ^a   Liao, Caiyun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Xinhui District Maternity   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; ESTRADIOL; FOLLITROPIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LEFLUNOMIDE; LUTEINIZING HORMONE; METHOTREXATE; MUELLERIAN INHIBITING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MENSTRUATION; OVARIAN RESERVE; OVARY FOLLICLE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ALKYLATING AGENTS; ANTI-MULLERIAN HORMONE; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GLUCOCORTICOIDS; HORMONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUTEINIZING HORMONE; MENSTRUATION; OVARY; TREATMENT OUTCOME;

EID: 84888877697     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2013.4255     Document Type: Article

References (29)

1. Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2008;26: 436-441.
2. Pasoto SG, Mendonça BB, Bonfá E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: Clinical, hormonal and therapeutic associations. Lupus 2002;11:175-180.
3. Fatnoon NN, Azarisman SM, Zainal D. Prevalence and risk factors for menstrual disorders among systemic lupus erythematosus patients. Singapore Med J 2008; 49:413-418.
4. Gonzalez-Crespo MR, Gomez-Reino JJ, Merino R, et al. Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol 1995;34: 737-741.
5. van Beek R, van den Heuvel-Eibrink M, Laven J, et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007;92:3869-3874.
6. van Rooij I, Tonkelaar I, Broekmans F, et al. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 2004;11:601-606.
7. Fanchin R, Schonauer L, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH, and LH on day 3. Hum Reprod 2003;18:323-327.
8. Seifer D, MacLaughlin D, Christian B, Feng B, Shelden R. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468-471.
9. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri D, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: Predictors of ovarian response in assisted reproductive technology? Br J Obstet Gynecol 2005;112:1384-1390.
10. Ficicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 2006;85:592-596.
11. Anderson R, Themmen A, Al-Qahtani A, Groome N, Cameron D. The effects of chemotherapy and long-term gonadotropin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006;21:2583-2592.
12. Kwee J, Elting ME, Schats R, McDonnell J, Lambalk CB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol 2007;15:5-9.
13. Hale GE, Hughes CL, Burger HG, Robertson DM, Fraser IS. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause 2009;16:50-59.
14. Saketos M, Sharma N, Santoro NF. Suppression of the hypothalamic- pituitary-ovarian axis in normal women by glucocorticoids. Biol Reprod 1993;49: 1270-1276.
15. Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol 1986;14:161-177.
16. Morrow J, Nelson L, Watts R, Isenberg D. Systemic lupus erythematosus. In: Autoimmune rheumatic disease. Oxford: Oxford University Press, 1999:56-103.
17. Mignot MH, Schoemaker J, Kleingeld M, Rao BR, Drexhage HA. Premature ovarian failure. The association with autoimmunity. Eur J Obstet Reprod Biol 1989;30:59-65.
18. Moncayo-Naveda H, Moncayo R, Benz R, Wolf A, Lauritzen C. Organ-specific antibodies against ovary in patients with systemic lupus erythematosus. Am J Obstet Gynecol 1989;160: 1227-1229.
19. Wheatcroft NJ, SaltC,Milford-WardA, Cooke ID, WeetmanAP. Identification of ovarian antibodies by immunofluorescence, enzyme-linked immunosorbent assay or immunoblotting in premature ovarian failure. Hum Reprod 1997;12: 2617-2622.
20. Lubovsky J, Visintin J, Boyers S, Asari T, Caldwell B, de-Cheney A. Ovarian antibodies detected by immobilized antigen immunoassay in patients with premature ovarian failure. J Clin Endocrinol Metab 1990;70:69-74.
21. Lubovsky J, Llanes B,Davies S, Binor Z, Radwanska E, Pong R. Ovarian autoimmunity: Greater frequency of autoantibodies in premature menopause and unexplained infertility than in general population. Clin Immunol 1999;90:368-374.
22. Chernyshov VP, Radysh TV, Gura IV, Tatarchuk TP, Khominskaya ZB. Immune disorders in women with premature ovarian failure in initial period. Am J Reprod Immunol 2001;46:220-225.
23. Roeiy A, Valesini G, Friberg J, et al. Autoantibodies and common idiotypes in men and women with sperm antibodies. Am J Obstet Gynecol 1988;158:596-603.
24. Lanir N, Zilberman M, Yron I, Tennenbaum G, Shechter Y, Brenner B. Reactivity patterns of antiphospholipid antibodies and endothelial cells: effect of antiendothelial antibodies on cell migration. J Lab Clin Med 1998;131:548-556.
25. Mizutani H, Kurata Y, Kosugi S, et al. Monoclonal anticardiolipin autoantibodies established from the (New Zealand white3BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum 1995;38:1382-1388.
26. Delgado Alves J, Kumar S, Isenberg DA. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford). 2003;42: 893-899.
27. Aikawa NE, Sallum AM, Pereira RM, et al. Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy. Clin Exp Rheumatol 2012;30:445-449.
28. Al-Maini MH, Mountz JD, Al-Mohri HA, et al. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus 2000;9:132-139.
29. Lawrenz B, Henes J, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus 2011;20:1193-1197.